Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Plaque Psoriasis: later-stage trial registry
10 of 46 indexed Plaque Psoriasis trials are currently recruiting, with more weight in Phase 3-4.
Corpus placement: #312 of 28,707 conditions by registered trial count.
46 US clinical trials · 10 currently recruiting · #312 of 28,707 conditions by registered trial count
Plaque Psoriasis: 46 US clinical trials tracked, 10 recruiting.
Plaque Psoriasis is the subject of 46 registered US clinical trials on ClinicalTrials.gov, 10 of them currently open to new participants. 30 are in Phase 3-4 (later-stage) and 15 in Phase 1-2 (earlier-stage). The most active sponsor is Janssen Research & Development, running 5 of these trials.
Enrollment posture brief
Registry condition plaque-psoriasis
OPEN 10 | RECR 22% | LATE 30 | EARLY 15 | RANK #312 | SPON 5
Volume-matched condition peers
Nearest open-share peer: Smoking (22% recruiting · 124 trials)
Plaque Psoriasis lists 10 open slots (22% of 46 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Plaque Psoriasis on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Plaque Psoriasis is recruiting below its size-band peers.
10 of 46 indexed trials (21.7%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Plaque Psoriasis trials is spread across many organizations.
Janssen Research & Development accounts for 5 of 46 trials (10.9%). 26 distinct sponsors appear on at least one study for this condition label.
-
Typical Plaque Psoriasis enrolment sits around 165 participants.
Median target enrolment is 165 among the 46 trials that report a genuine target (sentinel values excluded). 17 of those (37%) plan for fewer than 100 participants.
-
Plaque Psoriasis research is mostly interventional.
45 interventional and 1 observational studies make up this index (97.8% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
46 total, page 1 of 1
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
Bristol-Myers Squibb
NCT07116967
Psorcast Mobile Study
Sage Bionetworks
NCT05621369
A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis
Bristol-Myers Squibb
NCT06979453
Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis
Oruka Therapeutics
NCT07290569
A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis
Takeda
NCT07250802
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of ASC50 Tables in Healthy Participants and Participants With Plaque Psoriasis
Ascletis Pharma (China) Co., Limited
NCT07024602
An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis
Oruka Therapeutics
NCT07449702
Bimekizumab in Plaque Psoriasis
Icahn School of Medicine at Mount Sinai
NCT06336343
Guselkumab Immunogenetics
University of California, San Francisco
NCT04645355
Triamcinolone With Vitamin D Synergistic Efficacy in Psoriasis
Wright State University
NCT04036188
A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis
Takeda
NCT06550076
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
Alumis
NCT06846541
A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasis
Alumis
NCT06586112
A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001
Alumis
NCT06588738
A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
Janssen Research & Development
NCT06143878
A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis
Janssen Research & Development
NCT06934226
A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2)
Janssen Research & Development
NCT06220604
A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis
Janssen Research & Development
NCT06095115
A Study Comparing Zasocitinib (TAK-279) With Deucravacitinib in Adults With Plaque Psoriasis
Takeda
NCT06973291
A Study of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas (Scalp, Genital, and/or Palms of the Hands and the Soles of the Feet)
Janssen Research & Development
NCT06095102
Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of ESK-001 in Plaque Psoriasis
Alumis
NCT05739435
ORKA-001 Versus Placebo in Patients With Moderate-to-Severe Plaque Psoriasis
Oruka Therapeutics
NCT07090330
Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects
Organon and
NCT05172726
A Study of Apremilast in Pediatric Participants in Children With Mild to Moderate Plaque Psoriasis
Amgen
NCT06088199
A Study Comparing the Safety and Efficacy of Two Dosing Regimens of ABT-874 to Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis
AbbVie (prior sponsor, Abbott)
NCT00570986
The Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream in Subjects With Chronic Plaque Psoriasis
Arcutis Biotherapeutics
NCT03638258
An Efficacy and Safety Study of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO)
UCB Biopharma S.P.R.L.
NCT02326298
A Study to Evaluate the Efficacy and Safety of DC-806 in Participants With Moderate to Severe Plaque Psoriasis
DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company
NCT05896527
A Study to Evaluate the Efficacy and Safety of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO)
UCB Biopharma S.P.R.L.
NCT02326272
A Comparison of 000-0551 Lotion Versus Vehicle Lotion in Subjects With Plaque Psoriasis (Study -305)
Therapeutics
NCT01882647
A Comparison of 000-0551 Lotion Versus Vehicle Lotion in Subjects With Plaque Psoriasis (Study -304)
Therapeutics
NCT01871402
Safety and Efficacy of IDP-122 in the Treatment of Participants With Plaque Psoriasis
Bausch Health Americas
NCT02514577
Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis
Bausch Health Americas
NCT02462070
Study to Evaluate the Efficacy and Safety of JTE-451 in Subjects With Moderate to Severe Plaque Psoriasis
Akros Pharma
NCT03832738
A Comparison of 122-0551 Foam Versus Vehicle Foam in Subjects With Plaque Psoriasis
Therapeutics
NCT02367911
Clinical Study to Evaluate the Efficacy and Safety of DSXS in Patients With Mild to Moderate Plaque Psoriasis
Sun Pharmaceutical Industries
NCT02618759
Study To Assess Efficacy, Safety, Tolerability And Pharmacokinetics Of PF-07038124 Ointment In Participants With Atopic Dermatitis Or Plaque Psoriasis
Pfizer
NCT04664153
A Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study Of PF-06700841, With Bioavailability/Food Effect Investigation
Pfizer
NCT02310750
The Efficacy and Safety of TLL018 in Moderate-to-severe Plaque Psoriasis
Hangzhou Highlightll Pharmaceutical Co.
NCT05772520
Patient Satisfaction Following Twice Daily Dosing With DFD-01 in Subjects With Moderate Plaque Psoriasis
Primus Pharmaceuticals
NCT02749799
Subject Reported Target-lesion Numeric Rating Scale Evaluation by Subjects With Plaque Psoriasis Treated With Clobex® (Clobetasol Propionate) Spray 0.05%
Galderma R&D
NCT01893567
Study to Assess the Potential for Adrenal Suppression Following Treatment With DSXS in Patients With Plaque Psoriasis
Sun Pharmaceutical Industries
NCT02601469
Pharmacokinetics of 122-0551 and Its Effects on Adrenal Suppression
Therapeutics
NCT01698333
Adrenal Suppression and Absorption Study of Halobetasol Propionate Foam in Subjects 12-17 With Plaque Psoriasis
Mayne Pharma International Pty
NCT03992261
Maximal Use Study of Tapinarof Cream, 1% in Adults With Extensive Plaque Psoriasis
Organon and
NCT04042103
Patient Preference of Taclonex Ointment to Taclonex Scalp Suspension in Adult Subjects With Psoriasis Vulgaris
Wake Forest University
NCT01707043
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 12 |
| Phase 3 | 24 |
| Phase 4 | 6 |
Top Sponsors
Named interventions
Most-linked intervention names on Plaque Psoriasis records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Plaque Psoriasis trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Plaque Psoriasis page
46 registered trials, 10 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 10 Plaque Psoriasis trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Janssen Research & Development sponsors the most Plaque Psoriasis trials on record, review their full trial history before evaluating a specific study. See Janssen Research & Development's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Plaque Psoriasis condition card totals 46 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.